PPA Exposure Misclassification Bias Prevented, HSP Researchers Maintain
This article was originally published in The Tan Sheet
Executive Summary
Hemorrhagic Stroke Project procedures to measure participant recall and product classification prevented misclassification bias related to case and control subjects' phenylpropanolamine (PPA) exposure, Yale University researchers assert.
You may also be interested in...
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
An estimated 200-500 hemorrhagic strokes a year in people ages 18-49 can be attributed to phenylpropanolamine, FDA's Office of Postmarketing Drug Risk Assessment told the Nonprescription Drugs Advisory Committee at a meeting in Gaithersburg, Md. Oct. 19.